Welcome to our dedicated page for QuidelOrtho SEC filings (Ticker: QDEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on QuidelOrtho's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into QuidelOrtho's regulatory disclosures and financial reporting.
QuidelOrtho Corporation is appointing Micah Young as Chief Financial Officer and principal financial officer, effective July 6, 2026, succeeding retiring CFO Joseph M. Busky, who will remain through the transition and then serve as a special advisor.
Young, a seasoned medical technology finance executive and former CFO of Masimo Corporation, will receive a $750,000 annual base salary, an annual target cash bonus equal to 100% of base salary, a $500,000 cash sign-on bonus, and a one-time inducement grant of RSUs valued at $6,500,000 vesting over three years. He is also expected to receive 2027 equity grants valued at $5,000,000, split between time-based RSUs and stock options, along with severance and change-in-control protections consistent with other executives.
Busky will receive an annual base salary of $340,000 for six months after the effective date during the transition, then up to 24 months as special advisor at $100,000 per year, with continued eligibility for 2026 bonus and existing equity vesting terms.
QuidelOrtho Corporation reported the results of its 2026 Annual Meeting of Stockholders held on June 16, 2026. Stockholders elected all ten director nominees, each receiving over 56 million votes in favor, with several receiving more than 56.6 million votes for and relatively few votes withheld.
Stockholders also approved, on an advisory basis, the compensation of the company’s named executive officers, with 55,716,067 votes for, 1,486,910 against, and 22,228 abstentions, alongside 7,088,721 broker non-votes. In addition, they ratified the appointment of KPMG LLP as independent registered public accounting firm for the 2026 fiscal year, with 64,197,113 votes for, 97,367 against, and 19,446 abstentions.
QuidelOrtho Corp director Kenneth J. Widder reported routine equity compensation activity involving restricted stock units. On June 6, 2026, he acquired 273 and 910 shares of common stock at $0.00 per share through grants/awards.
These shares came from the release and conversion of previously reported restricted stock units into common stock, with 273 and 910 units exercised at a $0.00 conversion price. Footnotes explain that the restricted stock unit release had been deferred under QuidelOrtho’s deferred compensation program for participating non-employee directors and occurred according to his elected deferral schedule.
QuidelOrtho Corp director Mary Lake Polan, Ph.D. reported compensation-related equity activity involving restricted stock units and common shares. On June 6, 2026, she exercised a total of 973 restricted stock units at $0.00 per unit, each converting into one share of common stock under the company’s program.
These releases were previously reported awards whose delivery was deferred under QuidelOrtho’s deferred compensation program for non-employee directors. Following these transactions, she held 20,442 shares of common stock directly and 17,353 shares indirectly through an LLC. The filing reflects routine director equity compensation rather than open-market buying or selling.
QuidelOrtho Corp director Kenneth F. Buechler increased his direct stake through equity compensation rather than market buying. On June 6, 2026, he acquired 497 and 1,659 shares of Common Stock at $0.00 per share as grants linked to restricted stock units. These 2,156 shares came from the release and conversion of previously reported restricted stock units under QuidelOrtho's deferred compensation program for participating non-employee directors. Following the transactions, Buechler directly owns 110,906 common shares.
QuidelOrtho Corp director Michael Edward L. reported compensation-related equity activity. He received 1,252 shares of common stock through the release and conversion of restricted stock units on June 6, 2026, at a stated price of $0.00 per share as part of his director compensation. Following these awards and conversions, he holds approximately 29,433 common shares directly. Footnotes explain the restricted stock units were previously reported, each unit represents one common share, and their release was deferred under QuidelOrtho’s deferred compensation program for participating non-employee directors.
QuidelOrtho Corp director Matthew Strobeck increased his direct stake through equity compensation. On May 29, 2026, 6,829 restricted stock units vested and were converted into 6,829 shares of common stock at $0.00 per share, previously reported as RSUs.
Following this grant and conversion, he holds 34,604 common shares directly. He also reports indirect positions, including 38,145 shares held by Birchview Fund, LLC, where he has sole voting and dispositive power, and 16,630 shares in UGMA accounts for his children, which he disclaims as beneficially owned.
QuidelOrtho Corp director Kenneth J. Widder reported an equity award tied to restricted stock units. On May 29, 2026, 6,829 restricted stock units vested and were converted into 6,829 shares of common stock at no cash cost, reflecting a compensation-related grant rather than a market purchase.
Following these transactions, Widder directly holds 43,890 shares of QuidelOrtho common stock. The filing shows an exercise of the corresponding derivative position, leaving no remaining restricted stock units from this grant.
QuidelOrtho Corp director Mary Lake Polan, Ph.D., reported routine equity compensation activity involving restricted stock units and common shares. On May 29, 2026, 6,829 restricted stock units vested and were converted into 6,829 shares of common stock at a conversion price of $0.00 per share. These units had been previously reported and each unit represented the right to receive one share of QuidelOrtho common stock. Following the conversion, she held 19,469 shares of common stock directly, while a separate 17,353 shares of common stock were reported as held indirectly through an LLC.
QuidelOrtho Corp director Kenneth F. Buechler reported a compensation-related stock award and vesting of restricted stock units. On May 29, 2026, 6,829 restricted stock units vested and were converted into 6,829 shares of common stock at no exercise price. This is reflected as a grant/acquisition of common shares and an exercise of the corresponding restricted stock unit derivative, leaving no units from that grant outstanding. Following these transactions, Buechler directly holds 108,750 shares of QuidelOrtho common stock.